Novavax: Covid-19 Vaccine Gathering Momentum in Asia and Europe

Novavax (NVAX) investors have had to be patient, as delays have seen its Covid-19 vaccine lag competitors’ offerings. However, recently the vaccine has been showing evidence it could still play a prominent role in the ongoing global fight against the coronavirus.

On Wednesday, the company announced two positive developments. First off, the biotech announced that NVX-CoV2373 has been granted emergency use authorization (EUA) in the Philippines, where it will go to market under the brand name COVOVAX.

The Philippines is one of the world’s most populace countries, with over 110 million people, however, only 22% are considered fully vaccinated, although the country’s rigid social distancing measures have resulted in the lowest number of cases seen over the past 11 months. Nevertheless, the country was an early NVX-CoV2373 adopter and has already secured a supply of 30 million doses. Additionally, as Novavax’ vaccine can be kept in a standard fridge temperature for long periods it could be highly beneficial in the country.

Separately, the company said the European Medicines Agency (EMA) has initiated its evaluation of NVAX's application for conditional marketing authorization. The vaccine is under an accelerated timeline review, and could potentially gain approval “within weeks,” where it will receive the brand name Nuvaxovid. Recall, the company has an agreement with the E.U. to supply it with up to 200 million doses of the vaccine. Unlike the Philippines, the region has recently seen a big increase in cases.

The latter piece of news is especially encouraging, notes longtime NVAX proponent B. Riley’s Mayank Mamtani. “We believe the EU accelerated review potentially having a favorable readthrough to regulatory filings with key Western economies, notably U.K., EU, Canada and U.S,” the analyst said.

Approval in the UK, Canada, Australia and New Zealand could act as further catalysts

Here is a description of the technology behind Novavax’s Covid vaccine:

https://www.nebraskamed.com/COVID/moths-and-tree-bark-how-the-novavax-vaccine-works

Q: How does the Novavax vaccine work?

The Novavax COVID-19 vaccine contains a protein (made using moth cells) plus an adjuvant (made from tree bark). An adjuvant is an ingredient added to boost a person’s immune response, creating higher levels of antibodies.

The Novavax vaccine uses a telltale piece of the coronavirus: the notorious spike protein. All alone, the spike protein is harmless and can’t cause COVID-19. When your immune system encounters the lonely spike protein, it produces antibodies against it. This gives you protection against future COVID-19 infection.

“Unlike mRNA vaccines, the spike protein is already premade in the Novavax vaccine. It’s a shortcut,” explains Dr. Florescu. “All the synthesis happens outside the body and we just give the end product: the spike protein.”

Like other COVID-19 vaccines, Novavax does not cause COVID-19 infection. It can’t get you sick. This vaccine doesn’t contain either live or inactivated virus.

Q: How did they get the spike protein?

The Novavax method uses moth cells to make spike proteins:

Researchers select the desired genes that create certain SARS-CoV-2 antigens (spike protein).

Researchers put the genes into a baculovirus, an insect virus.

The baculovirus infects moth cells and replicates inside them.

These moth cells create lots of spike proteins.

Researchers extract and purify the spike proteins.
“The Novavax vaccine has no genetic material, only proteins,” says Dr. Florescu. “The vaccine technology is more traditional, and it’s very similar to a protein-based influenza vaccine.”. This is the same technology used in several existing vaccines for such diseases as Hepatitis and Tetanus.

Influenza vaccines have also used this moth cell factory method.

Q: What does the adjuvant (soapbark tree extract) do?

Adjuvants increase the immune response to a vaccine. In this vaccine, soapbark tree extract adjuvant makes achieving immunity possible with a smaller dose of the spike protein.

Matrix-M is the adjuvant used by Novavax. It is based on a saponin extracted from the soapbark tree (Quillaja saponaria). The soapbark extract encourages immune cells to activate, generating a more potent immune response.

Saponins are found naturally in various plant species like beans and green peas. They’re used in agriculture, animal feeds, veterinary vaccines and human food. Saponins can boost immune responses to proteins. Using the Matrix-M adjuvant, a smaller dose of spike protein achieves the desired immune response.

In the General/Chat forum, on a thread titled Novavax: Covid-19 Vaccine Gathering Momentum in Asia and Europe, fastrock wrote:

If I remember correctly, Noravax is a dead virus vax similar to polio or smallpox. Could someone confirm or deny please?

No, there's nothing traditional about Novavax. They grow spike proteins in moth cells and then harvest and purify the spike proteins. FWIW, they also said J&J was like the traditionally vaccines we grew up with - they were lying, of course. They know people used to trust 'vaccines' so now the marketing all speaks of 'traditional' etc.

You may have heard things about Novavax that aren't true. It's highly likely.

NOvavax is an injection of pure spike proteins - no mRNA or fragment of DNA this time. Just pure, toxic, damaging spike proteins. Once people became aware the spike proteins are the major problem with Covid 'vaccines' the developers started using euphemisms and different descriptive terms to hide spike proteins in products. I've seen articles about Novavax that try to make you think they have some other protein sub unit, instead of simply referring to spike proteins.

The first person to review NOvavax was reading from NOvavax's product release literature which referred to spike proteins.

His comments about Novavax are in the first half of the video below.

Below that, a link about how NOvavax, just like Moderna, was a failed company until given Covid 'vaccine' contract(s).

My notes on Dr. John Campbell's video "TUESDAY UPDATE" in which he reviews Novavax and a small Ivermectin study in Israel.
youtube.com ^ | Jun 15, 2021 | Dr. John Campbell and vanity

The long shot [Novavax Covid Vaccine]
sciencemag.org ^ | 06 Nov 2020: | Meredith Wadman

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.